Vermillion Receives Notice Of Allowance For Patent On Methods For Diagnosing Ovarian Cancer

AUSTIN, Texas, March 28, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, has received a notice of allowance from the United States Patent and Trademark Office for a patent, "Methods for Diagnosing Ovarian Cancer."

This patent further expands the list of biomarkers Vermillion has employed in the diagnosis or status determination of ovarian cancer. In this case, the granted claims cover the use of Protein C Inhibitor (PCI) in ovarian cancer tests using blood and several other sample types.

"Vermillion continues to expand its already extensive portfolio of biomarker-related patents in ovarian cancer and other important disease states," said Donald Munroe, Ph.D., chief science officer and VP of research & development at Vermillion. "The latest patent allowance further strengthens the ovarian cancer franchise behind our lead product, OVA1®, and offers creative new options to detect and manage this silent killer."

About OVA1OVA1 was the first FDA-cleared blood test for pre-surgical cancer diagnosis that achieved 99% accuracy in clinical trials for detecting epithelial ovarian cancers.(1) In other studies, OVA1 found 70% of malignancies missed by non-specialist pre-surgical assessment,(2) and it increased detection of malignancy over ACOG guidelines from 77% to 94%.(3)  As the first protein-based, In Vitro Diagnostic Multi-Variate Index Assay (IVDMIA) cleared by the FDA, OVA1 also represents a new class of software-based diagnostics.

Citings:1) Ueland, FR, et al. Obstet Gynecol 2011:VOL 117, NO. 6, June 20112) Ueland, FR, et al. Obstet Gynecol 2011:VOL 117, NO. 6, June 20113) Miller R, et al. Obstet Gynecol 2011:VOL 117, NO. 6, June 2011



About VermillionVermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found at www.vermillion.com .

1 2 3 Next › Last »